{Reference Type}: Journal Article
{Title}: Recalcitrant Folliculitis Decalvans Treatment Outcomes With Biologics and Small Molecule Inhibitors.
{Author}: Fakhoury T;Urban K;Ettefagh L;Nami N;
{Journal}: Cutis
{Volume}: 113
{Issue}: 5
{Year}: 2024 May
{Factor}: 1.675
{DOI}: 10.12788/cutis.1023
{Abstract}: Folliculitis decalvans (FD) is a rare primary neutrophilic cicatricial alopecia that commonly displays resistance to traditional therapies and remains challenging to treat. Currently, data are lacking with recommendations for therapy-recalcitrant FD. A systematic review was conducted to analyze biologics, small molecule inhibitors, tumor necrosis factor (TNF) inhibitors, Janus kinase (JAK) inhibitors, phosphodiesterase 4 (PDE4) inhibitors, and monoclonal antibodies utilized in the treatment of recalcitrant FD.